199 related articles for article (PubMed ID: 19738020)
21. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
MacGowan AP; Rogers CA; Holt HA; Wootton M; Bowker KE
Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate.
Aliabadi FS; Lees P
J Vet Pharmacol Ther; 2002 Jun; 25(3):161-74. PubMed ID: 12081611
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of several fluoroquinolones and beta-lactams in terms of their capability to restrict the selection of fluoroquinolone-resistant Salmonella: in vitro models.
Cebríán L; Rodríguez JC; Escribiano I; Royo SG
APMIS; 2007 Dec; 115(12):1376-82. PubMed ID: 18184408
[TBL] [Abstract][Full Text] [Related]
25. Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.
Kesteman AS; Perrin-Guyomard A; Laurentie M; Sanders P; Toutain PL; Bousquet-Mélou A
Antimicrob Agents Chemother; 2010 Jul; 54(7):2960-4. PubMed ID: 20457820
[TBL] [Abstract][Full Text] [Related]
26. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.
Shams WE; Evans ME
Drugs; 2005; 65(7):949-91. PubMed ID: 15892589
[TBL] [Abstract][Full Text] [Related]
27. Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination.
Firsov AA; Vostrov SN; Lubenko IY; Zinner SH; Portnoy YA
Int J Antimicrob Agents; 2004 Jan; 23(1):60-6. PubMed ID: 14732315
[TBL] [Abstract][Full Text] [Related]
28.
Zhou YF; Tao MT; Huo W; Liao XP; Sun J; Liu YH
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264844
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.
Harada Y; Morinaga Y; Kaku N; Nakamura S; Uno N; Hasegawa H; Izumikawa K; Kohno S; Yanagihara K
Clin Microbiol Infect; 2014 Nov; 20(11):O831-9. PubMed ID: 24813594
[TBL] [Abstract][Full Text] [Related]
30. Significance of low-level resistance to ciprofloxacin in Klebsiella pneumoniae and the effect of increased dosage of ciprofloxacin in vivo using the rat granuloma pouch model.
Fuursted K; Schumacher H
J Antimicrob Chemother; 2002 Sep; 50(3):421-4. PubMed ID: 12205069
[TBL] [Abstract][Full Text] [Related]
31. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.
Blondeau JM
Vet Dermatol; 2009 Oct; 20(5-6):383-96. PubMed ID: 20178475
[TBL] [Abstract][Full Text] [Related]
32. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamics: relation to antimicrobial resistance.
Rybak MJ
Am J Med; 2006 Jun; 119(6 Suppl 1):S37-44; discussion S62-70. PubMed ID: 16735150
[TBL] [Abstract][Full Text] [Related]
34. Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.
Haritova AM; Rusenova NV; Parvanov PR; Lashev LD; Fink-Gremmels J
Antimicrob Agents Chemother; 2006 Nov; 50(11):3779-85. PubMed ID: 16940071
[TBL] [Abstract][Full Text] [Related]
35. Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin.
MacGowan A; Rogers C; Holt HA; Wootton M; Bowker K
J Antimicrob Chemother; 2000 Jul; 46(1):73-8. PubMed ID: 10882692
[TBL] [Abstract][Full Text] [Related]
36. Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance.
Xu L; Wang H; Yang X; Lu L
BMC Vet Res; 2013 Jun; 9():126. PubMed ID: 23800340
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone].
Parra-Ruiz J; Hernández-Quero J
Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254
[TBL] [Abstract][Full Text] [Related]
38. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration.
Fukuda Y; Takahata M; Mitsuyama J
J Infect Chemother; 2006 Feb; 12(1):1-8. PubMed ID: 16506083
[TBL] [Abstract][Full Text] [Related]
40. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones.
Blondeau JM; Blondeau LD; Hesje C; Borsos S
J Chemother; 2006 Aug; 18(4):366-72. PubMed ID: 17024791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
